81819-90-1

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
3-AMINO-4-METHYL-6-PHENYLPYRIDAZINE is used as a key intermediate in the synthesis of various pharmacologically active compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in the Treatment of Medical Conditions:
3-AMINO-4-METHYL-6-PHENYLPYRIDAZINE is employed as a potential therapeutic agent for the treatment of various medical conditions. Its specific applications may vary depending on the condition being targeted and the drug formulations being developed.
Safety Considerations:
It is crucial to handle 3-AMINO-4-METHYL-6-PHENYLPYRIDAZINE with caution and adhere to proper safety protocols due to its potential hazards. This ensures the safety of researchers and the effectiveness of the compound in its intended applications.

InChI:InChI=1/C11H11N3/c1-8-7-10(13-14-11(8)12)9-5-3-2-4-6-9/h2-7H,1H3,(H2,12,14)

Upstream product

• 28657-39-8 3-chloro-4-methyl-6-phenylpyridazine 
• 32723-48-1 3-hydrazino-4-methyl-6-phenyl-pyridazine 
• 13300-09-9 4-methyl-6-phenylpyridazin-3(2H)-one 

Downstream Products

• 81819-94-5 (4-Methyl-6-phenyl-pyridazin-3-yl)-(6-phenyl-pyridazin-3-yl)-amine 
• 105537-95-9 6-Amino-1-(3-ethoxycarbonyl-1-methyl-propyl)-5-methyl-3-phenyl-pyridazin-1-ium; bromide 
• 105537-92-6 6-Amino-1-(4-ethoxycarbonyl-butyl)-5-methyl-3-phenyl-pyridazin-1-ium; bromide 
• 105537-93-7 ethyl ester of 2-(5-carboxypentyl)-3-amino-4-methyl-6-phenylpyridazinium bromide 
• 81819-92-3 3-<β-naphthylazo>-4-methyl-6-phenylpyridazine 
• 105537-55-1 6-Amino-1-(3-cyano-propyl)-5-methyl-3-phenyl-pyridazin-1-ium; bromide 
• 161125-88-8 3-(N-pivaloylamino)-4-methyl-6-phenylpyridazine 
• 111247-73-5 3-imino-2-[(3-methoxy-5-isoxazolyl)-methyl] 4-methyl-6-phenyl-2,3-dihydro-pyridazine 
• 105537-61-9 6-Amino-1-(3-carboxy-1-methyl-propyl)-5-methyl-3-phenyl-pyridazin-1-ium; bromide 
• 105537-60-8 6-Amino-1-(3-carboxy-butyl)-5-methyl-3-phenyl-pyridazin-1-ium; bromide 
• 105537-59-5 2-(5-carboxypentyl)-3-amino-4-methyl-6-phenylpyridazinium bromide 
• 105537-57-3 6-Amino-1-(2-carboxy-ethyl)-5-methyl-3-phenyl-pyridazin-1-ium; bromide 
• 105562-24-1 6-Amino-1-(3-carbamoyl-propyl)-5-methyl-3-phenyl-pyridazin-1-ium; bromide 
• 105537-54-0 2-(3-carbethoxypropyl)-3-amino-4-methyl-6-phenylpyridazinium bromide 

Relevant academic research and scientific papers

Synthesis of Pyridazine Derivatives via Aza-Diels-Alder Reactions of 1,2,3-Triazine Derivatives and 1-Propynylamines

A highly regioselective method was developed for the preparation of pyridazine derivatives via the aza-Diels-Alder reaction of 1,2,3-triazines with 1-propynylamines under neutral conditions. This methodology allowed direct access to a wide range of 6-aryl-pyridazin-3-amines in high yields with good functional group compatibility. Key features of this strategy included a broad substrate scope and simple, metal-free, and neutral reaction conditions.

Synthesis and Structure-Activity Relationships of Series of Aminopyridazine Derivatives of γ-Aminobutyric Acid Acting as Selective GABA-A Antagonists

We have recently shown that an aryloaminopyridazine derivarive of GABA, SR 95103 , is a selective and competitive GABA-A receptor antagonist.In order to further explore the structural requirements for GABA receptor affinity, we synthesized a series of 38 compounds by attaching various pyridazinic structures to GABA or GABA-like side chains.Most of the compounds displaced GABA from rat brain membranes.All the active compounds antagonized the GABA-elicited enhancement of diazepam binding, strongly suggesting that all these compounds are GABA-A receptor antagonists.None of the compounds that displaced GABA from rat brain membranes interacted with other GABA recognition sites (GABA-B receptor, GABA uptake binding site, glutamate decarboxylase, GABA-transaminase).They did not interact with the Cl- ionophore associated with the GABA-A receptor and did not interact with the benzodiazepine, strychnine, and glutamate binding sites.Thus these compounds appear to be specific GABA-A receptor antagonists.In terms of structure-activity, it can be concluded that a GABA moiety bearing a positive charge is necessary for optimal GABA-A receptor recognition.Additional binding sites are tolerated only if they are part of a charge-delocalized amidinic or guanidinic system.If this delocalization is achieved by linking a butyric acid moiety to the N(2) nitrogen of a 3-aminopyridazine, GABA-antagonistic character is produced.The highest potency (ca.250 times bicuculline) was observed when an aromatic ? system, bearing electron-donating substituents, was present on the 6-position of the pyridazine ring.

Herbicidal pyridazines and method for controlling undesirable plant species

This invention relates to a method for controlling undesirable monocotyledonous and dicotyledonous plant species by applying to the foliage thereof or to soil containing seeds or other propagating organs of said plant species, a herbicidally-effective amo

Reactions of 3-Chloropyridazines with Some Nucleophilic Reagents

3-Chloro-6-phenylpyridazine (1a) and its 4-methyl derivative (1b) react with sodamide, hydrazines, 3-aminopyridazines and phenothiazine in polar and non-polar solvents as well as by fusion to give different products.The structures assigned to the products have been confirmed by their IR spectra.